Comparison of screening results of urban cancer early diagnosis and early treatment project in 2023 and 2022 in Wuwei City

Abstract Objective To compare the screening results of urban cancer early diagnosis and early treatment project in Liangzhou District of Wuwei City in 2023 and 2022, analyze the characteristics of screening population changes, and provide optimization suggestions for the future development of urban cancer project. Methods The 2022–2023 screening data were extracted from the urban cancer screening system and matched with the telephone follow-up results of the cancer population, and the characteristics of the two-year screening population were compared by gender and age. Chi-square test was used for comparison between groups. Results From 2022 to 2023, a total of 6098 people participated in questionnaire assessment and 4400 people participated in clinical screening. In 2023, 1587 people were at high risk, with a high risk rate of 92.61%; In 2022, 3301 people are at high risk, with a high risk rate of 80.06%. The two-year data comparison found that both the overall risk rate comparison and the gender comparison, the risk rate in 2023 was higher than that in 2022. However, by age group comparison, it is found that in 2022, the middle age group has a higher risk rate, and in 2023, the high age group has a higher risk rate. In 2023, 1,975 people will participate in assessment and 1,560 people will participate in clinical screening. The participation rate of clinical screening was 78.99%. In 2023, 36.35% men and 63.65% women will participate in clinical screening. In 2022, 33.06% of men and 66.94% of women participated in clinical screening. The sex composition ratio of the population participating in clinical screening at two years was similar. The proportion of people participating in clinical screening in 2022 and 2023 was compared by age group, and it was found that the three age groups of 50–64 years old accounted for the largest number of people, and the 70–74 years old group accounted for the least. Compared with 2022, the detection rate of cancer in all parts of 2023 has decreased, and the detection rate of other positive lesions besides cancer in liver, breast, colorectal and upper digestive tract has also decreased, but the detection rate of other positive lesions besides cancer in lung has increased by 17.98%. Conclusion There is still room for improvement in the participation rate of clinical screening, and more measures should be taken to encourage high-risk groups to complete clinical screening programs. In addition, the ability to detect diseases in staff still needs to be improved.